RLMD - שווי פעילות לרווח לפני ריבית, מסים ופחת Relmada Therapeutics, Inc.

Relmada Therapeutics (RLMD) is developing innovative intravenous treatments for major depressive disorder, while the asset's market price remains decoupled from sales. Finances are based on clinical trial expenditures without positive cash flow. This EV/EBITDA valuation chart is fixed at 0.00. The brand is rapidly gaining authority in psychiatry by offering advanced therapies for CNS disorders with prolonged effects.

Outsourcing production and testing minimizes capital expenditures for Relmada Therapeutics (RLMD), allowing the company to maintain high operational flexibility. The current Enterprise Value to EBITDA ratio 0.00 reflects the relationship between the total market value of the business and its EBITDA, helping investors assess the level of debt load and the fundamental overvaluation of the asset relative to its ability to generate cash flow.